However, despite the tremendous progress that has been made in understanding the functions and signaling pathways of TRIM proteins responsible for tumor, limited TRIM protein-based therapeutics for cancers are approved by the U.S. Food and Drug Administration (FDA) or entering clinical trials. This evidence concerns the gene TRAT1 and cancer.